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ABSTRACT
Introduction: People living with advanced chronic
obstructive pulmonary disease (COPD) suffer from
significant morbidity, reduced quality of life and high
mortality, and are likely to benefit from many aspects
of a palliative care approach. Prognostic estimates are
a meaningful part of decision-making and better
evidence for such estimates would facilitate advance
care planning. We aim to provide quality evidence on
known prognostic variables and scores which predict a
prognosis in COPD of <12 months for use in the
community.
Methods and analysis: We will conduct a systematic
review of randomised or quasi-randomised controlled
trials, prospective and retrospective longitudinal cohort
and case–control studies on prognostic variables,
multivariate scores or models for COPD. The search
will cover the period up to April 2016. Study selection
will follow the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines, with
data extraction using fields from the Critical Appraisal
and Data Extraction for Systematic Reviews of
Prediction Modelling Studies (CHARMS) checklist for
multivariate models, and study quality will be assessed
using a modified version of the Quality In Prognosis
Studies (QUIPS) tool.
Ethics and dissemination: The results will be
disseminated through peer-reviewed publications and
national and international conference presentations.
Systematic review registration number:
CRD42016033866.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a complex, heterogeneous collec-
tion of conditions characterised by progressive
irreversible expiratory airﬂow limitation. The
prevalence of COPD is increasing globally
and it is projected to be not only the third
leading cause of death but also the seventh
leading cause of disability-adjusted life years
lost worldwide by 2030, representing an
important public health challenge.1 Patients
with advanced COPD have signiﬁcant
morbidity, reduced quality of life and high
mortality.2–6
Despite national7 and international8 guide-
lines recommending a palliative care
approach in severe COPD, patients are
unlikely to access specialist services or ele-
ments of ‘general’ palliative care such as
advance care planning, promotion of phy-
sical and psychosocial health and family or
carer support.6 9–12 Systematic identiﬁcation
of patients approaching the ‘end-of-life’ is a
key recommendation of the end-of-life care
strategy.13 The unpredictable disease trajec-
tory of COPD14 makes this difﬁcult. Policy lit-
erature uses the last year of life as the
measure of those who are approaching
death, and states that identiﬁcation of this
group is the ﬁrst step in any palliative care
process. However, there is no ‘gold standard’
method for predicting prognosis in COPD
and no clear guidance on how to identify
those in the last year of life. Easily measur-
able physiological parameters do not correlate
well with mortality for individuals.15 There are
alternative methods for identifying patients
who may beneﬁt from speciﬁc services, such
as needs-based assessment.16 However, there
Strengths and limitations of this study
▪ Broad search strategy planned in order to iden-
tify a range of individual prognostic variables
and multidimensional scores.
▪ A focus on prognostic variables available in clini-
cal practice (rather than, eg, genomics), such
that the results will be meaningful to current
practice.
▪ The use of validated protocols and tools for data
extraction, risk of bias assessment and reporting.
▪ Search restricted to patients with relatively stable
disease, so we are unable to comment on prog-
nostic variables of most use during or immedi-
ately after an exacerbation.
▪ Despite rigorous use of protocols, there is a sub-
jective element to any quality or risk of bias
assessment.
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are growing calls from patients, healthcare professionals
and policymakers for better tools to aid prognostication
which they see as a meaningful part of decision-
making.17 18 Clinician predictions of survival are often
inaccurate, and improvement in accuracy of prognostic
tools has been identiﬁed as a research priority.19
A number of variables have been identiﬁed which are
useful in making predictions about prognosis in COPD,
in addition to the degree of airﬂow obstruction which
was the historical way of staging the disease.20 Scores
that combine a number of variables have also been
developed, in recognition of the fact that COPD is a
multisystem disease. None of these scores are in wide-
spread routine clinical use. This is partly because some
variables used in these scores are not captured during
routine care. The most well-validated prognostic score in
COPD is the BODE (body mass index (BMI), FEV1%
(forced expiratory volume in 1 s, % predicted for age
and sex), MRC dyspnoea (Medical Research Council dys-
pnoea score) and 6MWT (6 min walk test)) index.21
However, this has signiﬁcant limitations as it requires a
6MWT, not routinely performed or recorded in primary
care. A modiﬁcation of the BODE score, the ADO22
(age, MRC dyspnoea, FEV1%), has been developed to
address this problem. These scores were developed in
small cohorts, although efforts to modify and validate
them in larger cohorts and different settings have
demonstrated some external validity.23–25
A systematic review of multidimensional prognostic
indices in COPD searched the literature up to
September 2010.26 This study will have some important
differences: we will consider the strength and utility not
only of composite scores but also of individual prognos-
tic variables. The only outcome of interest will be mor-
tality, and not exacerbation or hospitalisation; and our
focus will speciﬁcally be on prediction of prognosis
towards the end of life (<12 months).
METHODS AND ANALYSIS
Aim
We aim to investigate known prognostic variables and
scores that predict prognosis in COPD. We are speciﬁ-
cally interested in those variables that contribute to risk
assessment of patients in the community (ie, not hospi-
talised) for death within <12 months. In developing this
protocol, we referred to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses protocols
(PRISMA-P) 2015 statement,27 a guide for the standard
reporting of systematic review protocols.
Inclusion criteria (participants, interventions,
comparisons and outcomes)
Participants: Adults ≥35 years old with COPD as deﬁned
by GOLD.1
Interventions: We will include all randomised or
quasi-randomised controlled trials, and prospective and
retrospective longitudinal cohort and case–
control studies which investigate prognostic variables,
multivariate scores or models for COPD. We will include
studies that describe the development, validation or
impact assessment of prediction models.
Comparisons: Comparators and controls are less rele-
vant in prognostic than intervention studies and may be
absent in cohort studies.
Outcomes: The primary outcome of interest will be all-
cause mortality ≤12 months following recording of prog-
nostic variable or score.
Exclusion criteria
We will exclude the following literature: abstracts only
(eg, conference paper), case studies and reviews; studies
that are on patients with α-1-antitrypsin deﬁciency, or
those who have undergone lung transplantation, lung
volume reduction surgery or comparative interventional
bronchoscopic procedures; studies in which the diagnos-
tic criteria for COPD is unclear or does not meet GOLD
criteria; studies in which people with COPD form a sub-
group and no separate reporting is available; studies
requiring hospitalisation to acquire or measure the prog-
nostic variable or score; studies examining short-term
prognosis following an exacerbation or hospitalisation;
studies that investigate prognostic markers not easily
available in clinical practice (eg, biomarkers in develop-
ment, invasive investigations); and studies in which the
only exposure is occupational or environmental (eg, air
pollution).
Literature search
We will search Ovid MEDLINE, EMBASE, the Cochrane
database, Cochrane CENTRAL, DARE and CINAHL up
to 30 April 2016. We will use medical subject heading
and text words related to COPD, and broad strategies to
identify prognostic studies and prognostic markers,
focused on advanced disease and the end of life (see
ﬁgure 1). Recognising potential limitations of electronic
search strategies, we will supplement our search to iden-
tify potentially relevant studies from other sources,
including reference lists of included studies, index-
related articles on PubMed, and existing relevant reviews
as well as Google Scholar search and ProQuest. Where
necessary, authors will be contacted directly.
Selection of studies and extraction of data
Two authors will scan the titles and abstracts of all litera-
ture retrieved by the initial search against inclusion and
exclusion criteria and select articles for full-text review.
All data will be downloaded to Zotero28 for data man-
agement. Two authors will review the full-text articles to
assess eligibility for inclusion in the report. Differences
of opinion will be resolved by consensus, or by arbitra-
tion by a third reviewer. The authors will extract data
independently using a prespeciﬁed data extraction tool.
This will include details of the study setting, study
design, population, diagnostic criteria for COPD
(including cut-points for FEV1% predicted), method of
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measurement of each prognostic variable and outcome
deﬁnition. In addition, it will include ﬁelds relevant to
multivariate models based on the CHARMS checklist29
such as modelling method, handling of predictors,
method for selection of predictors, shrinkage of pre-
dictor weights, univariate and multivariate associations,
model performance and evaluation. This will be piloted
on the ﬁrst ﬁve full-text reviews to ensure standardised
use of the tool. The process of literature selection and
reasons for exclusion will be fully documented and a
PRISMA27 ﬂow diagram will be constructed.
Quality assessment
Two reviewers will assess quality and risk of bias of eligible
studies based on prespeciﬁed domains. We will use an
approach based on the Quality In Prognosis Studies
(QUIPS) tool,30 speciﬁcally designed for prognostic
reviews. We will consider questions under six domains:
study participation and attrition, prognostic factor mea-
surement, outcome measurement, confounding measure-
ment and account, analysis and other. Consensus will be
reached by discussion, or by arbitration by a third reviewer.
Data synthesis
Owing to clinical and methodological heterogeneity in
potentially included studies identiﬁed in the scoping
review, it is not expected that formal meta-analysis will
be possible. The planned method for evidence synthesis
is therefore a narrative synthesis of all identiﬁed evi-
dence. We will summarise the range of outcome predic-
tors that have been studied to date. With regard to
composite scores, we will assess not only the quality of
model building but also the degree to which the scores
have been externally validated and to what degree clini-
cal utility and impact has been assessed.
We anticipate that many of the studies will be in
restricted populations, such as trial populations, that
may not represent the population of patients with COPD
in the community. We will thus be cognisant of and
comment on possible spectrum bias31 and the implica-
tions for generalisability of ﬁndings. An assessment of
the strength of evidence for each prognostic variable or
score included will be formulated based on GRADE evi-
dence proﬁles.32
ETHICS AND DISSEMINATION
No ethical approval is required, since this study is a syn-
thesis of published studies. The results will be submitted
for peer-reviewed publication and will be presented at
national and international conferences.
The protocol has been registered in the PROSPERO
database: CRD42016033866. Any amendments to the
study protocol will be documented contemporaneously
on the PROSPERO database site.
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